Zacks Research Upgrades Roche (OTCMKTS:RHHBY) to Hold

Roche (OTCMKTS:RHHBY) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

RHHBY has been the subject of several other research reports. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective on the stock in a research note on Friday, August 7th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Roche has an average rating of “Hold” and an average target price of $60.00.

Roche Stock Performance

Shares of OTCMKTS:RHHBY opened at $58.47 on Monday. The company has a 50 day moving average price of $53.58 and a two-hundred day moving average price of $52.95. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche has a 52 week low of $39.50 and a 52 week high of $60.85.

Institutional Trading of Roche

Hedge funds have recently bought and sold shares of the stock. McIlrath & Eck LLC bought a new position in Roche in the first quarter valued at approximately $39,000. Oakworth Capital Inc. increased its position in shares of Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after acquiring an additional 285 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in shares of Roche during the fourth quarter worth $192,000. Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Roche during the first quarter worth $208,000. Finally, Renasant Bank bought a new stake in Roche in the 2nd quarter valued at $210,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.